Tanaka Toshiyuki, Motegi Tomoki, Mori Misaki, Sumikawa Nanami, Maeda Kaito, Iimori Yasumasa, Akiyoshi Hideo
Laboratory of Veterinary Surgery, School of Veterinary Science, Osaka Metropolitan University, Osaka, Japan.
Section of Computational Biomedicine, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, USA.
BMC Res Notes. 2024 Dec 2;17(1):357. doi: 10.1186/s13104-024-07016-y.
Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the expression of target genes. Therefore, the efficacy of the targeted therapies for canine HCC remains unclear.
Liver specimens were obtained from 11 dogs with HCC and four dogs without HCC. We performed RNA seq using the mRNA extracted from the specimens. Differentially expressed genes (DEGs) between canine HCC and normal liver were explored based on previously reported molecular-targeted agents for human tumours. PARP3, DNMT1, FGF19, FGF23, and RET DEGs were upregulated, whereas KIT, FGFR2, and FGF21 DEGs were downregulated.
无法切除的犬肝细胞癌（HCC）的非手术治疗选择有限。索拉非尼是一种针对无法切除的犬HCC的靶向治疗药物。然而，关于靶基因表达的报道有限。因此，犬HCC靶向治疗的疗效仍不明确。
从11只患有HCC的犬和4只未患HCC的犬获取肝脏标本。我们使用从标本中提取的mRNA进行RNA测序。基于先前报道的针对人类肿瘤的分子靶向药物，探索犬HCC与正常肝脏之间的差异表达基因（DEG）。PARP3、DNMT1、FGF19、FGF23和RET DEG上调，而KIT、FGFR2和FGF21 DEG下调。
